Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy


This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.

This is a preview of subscription content, log in to check access.


  1. 1.

    Krenning EP, Bakker WH, Breeman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.Lancet 1989; 1: 242–244.

  2. 2.

    Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumours.N Engl J Med 1990; 323: 1246–1249.

  3. 3.

    Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody.Lancet 1995; 346: 1662–1666.

Download references

Author information

Correspondence to A. Otte.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Otte, A., Jermann, E., Behe, M. et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24, 792–795 (1997).

Download citation

Key words

  • Somatostatin receptor-mediated internal radiotherapy
  • DTPA-d-Phe1-octreotide (OctreoScan)
  • DOTA-d-Phe1-Tyr3-octreotide (DOTATOC)
  • Indium-111
  • Yttrium-90